DK2879691T3 - Fremgangsmåder og sammensætninger til inaktivering af kappebærende vira - Google Patents

Fremgangsmåder og sammensætninger til inaktivering af kappebærende vira Download PDF

Info

Publication number
DK2879691T3
DK2879691T3 DK13750235.7T DK13750235T DK2879691T3 DK 2879691 T3 DK2879691 T3 DK 2879691T3 DK 13750235 T DK13750235 T DK 13750235T DK 2879691 T3 DK2879691 T3 DK 2879691T3
Authority
DK
Denmark
Prior art keywords
disabling
creative
wear
compositions
methods
Prior art date
Application number
DK13750235.7T
Other languages
Danish (da)
English (en)
Inventor
Lynn Edward Conley
Yinying Tao
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Application granted granted Critical
Publication of DK2879691T3 publication Critical patent/DK2879691T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation
    • C12N2710/16763—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • C12N2740/13063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK13750235.7T 2012-08-06 2013-08-06 Fremgangsmåder og sammensætninger til inaktivering af kappebærende vira DK2879691T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261680039P 2012-08-06 2012-08-06
PCT/US2013/053781 WO2014025771A2 (en) 2012-08-06 2013-08-06 Methods and compositions for inactivating enveloped viruses

Publications (1)

Publication Number Publication Date
DK2879691T3 true DK2879691T3 (da) 2019-06-11

Family

ID=48986268

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13750235.7T DK2879691T3 (da) 2012-08-06 2013-08-06 Fremgangsmåder og sammensætninger til inaktivering af kappebærende vira

Country Status (5)

Country Link
US (2) US10188732B2 (enExample)
EP (2) EP2879691B1 (enExample)
JP (2) JP6465800B2 (enExample)
DK (1) DK2879691T3 (enExample)
WO (1) WO2014025771A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10188732B2 (en) 2012-08-06 2019-01-29 Biogen Ma Inc. Methods and compositions for inactivating enveloped viruses
US11414712B2 (en) 2014-09-17 2022-08-16 Helixbind, Inc. Methods and devices for detecting and identifying microorganisms
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
WO2017147267A1 (en) * 2016-02-24 2017-08-31 Bio-Rad Laboratories, Inc. Methods and compositions for fluorescence detection
AU2017312785B2 (en) 2016-08-16 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
KR102759512B1 (ko) 2016-10-25 2025-02-03 리제너론 파아마슈티컬스, 인크. 크로마토그래피 데이터 분석을 위한 방법 및 시스템
EP3446710A1 (en) * 2017-08-25 2019-02-27 Glenmark Pharmaceuticals S.A. Methods of inactivating viral contaminants
CA3075853A1 (en) * 2017-09-18 2019-03-21 Bayer Healthcare Llc Methods of inactivation of viruses using n-methylglucamide and its derivatives
WO2019060062A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals Inc. METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREFROM
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
TWI919355B (zh) 2018-07-02 2026-03-21 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
PE20211140A1 (es) 2018-11-15 2021-06-25 Bayer Healthcare Llc Metodos de inactivacion virica para la fabricacion continua de anticuerpos
EA202192422A1 (ru) 2019-03-05 2021-12-09 Ридженерон Фармасьютикалз, Инк. Человеческий сывороточный альбумин в составах
KR20210142670A (ko) 2019-03-19 2021-11-25 암젠 인크 바이러스 불활성화를 위한 대체 세제
CN110424030B (zh) * 2019-08-30 2020-06-30 广州三孚新材料科技股份有限公司 无氰碱性电镀铜液及其制备和在挠性印刷线路板中的应用
US20230183656A1 (en) * 2020-05-14 2023-06-15 Merck Patent Gmbh Methods and compositions for purifying adeno associated virus particles or adenoviruses
US11643641B2 (en) 2021-03-04 2023-05-09 Malireddy S. Reddy Prevention of viral transmission by naked genetic material
WO2022268811A1 (en) 2021-06-21 2022-12-29 Uniqure Biopharma B.V. Improved lysis procedures
WO2024115344A1 (en) 2022-11-29 2024-06-06 Merck Patent Gmbh Method for inactivating enveloped viruses

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE242716C (enExample)
DD242716A3 (de) * 1981-08-28 1987-02-11 Adw Der Ddr Inst F Chem Techno Verfahren zur herstellung von gereinigten antigenen bzw. biopraeparaten
DE3704550A1 (de) * 1987-02-13 1988-08-25 Behringwerke Ag Verfahren zur inaktivierung huellhaltiger viren in mittels einer zelle in vitro hergestellten protein-praeparationen
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5314917A (en) * 1991-03-22 1994-05-24 E. B. Michaels Research Associates, Inc. Method for inactivating enveloped viruses and sperm
FR2805163A1 (fr) * 2000-02-21 2001-08-24 Pf Medicament Utilisation d'un detergent de type zwittergent pour la preparation d'une composition pharmaceutique destinee a etre administree par voie nasale
US6635679B2 (en) * 2001-05-14 2003-10-21 Akzo Nobel N.V. Methods and compositions for inactivating viruses
CN1901935A (zh) 2003-12-30 2007-01-24 惠氏公司 具有改进耐受性的免疫原组合物中的疏水性蛋白调配物
ES2377884T3 (es) * 2005-11-04 2012-04-02 Novartis Vaccines And Diagnostics S.R.L. Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores
EP1970440A1 (en) * 2007-03-06 2008-09-17 Qiagen GmbH Polymerase stabilization by ionic detergents
BR112013015113B1 (pt) 2010-12-15 2023-01-31 Takeda Pharmaceutical Company Limited Método de inativar um vírus contendo envelope lipídico
GB201216121D0 (en) * 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
US10188732B2 (en) 2012-08-06 2019-01-29 Biogen Ma Inc. Methods and compositions for inactivating enveloped viruses

Also Published As

Publication number Publication date
WO2014025771A3 (en) 2014-04-17
US10188732B2 (en) 2019-01-29
US10702603B2 (en) 2020-07-07
WO2014025771A2 (en) 2014-02-13
EP3456352A1 (en) 2019-03-20
JP6833788B2 (ja) 2021-02-24
JP2015525572A (ja) 2015-09-07
JP2019037234A (ja) 2019-03-14
EP2879691B1 (en) 2019-03-27
US20150306223A1 (en) 2015-10-29
EP2879691A2 (en) 2015-06-10
US20190175738A1 (en) 2019-06-13
JP6465800B2 (ja) 2019-02-06

Similar Documents

Publication Publication Date Title
DK2890780T3 (da) Fremgangsmåder og sammensætninger til behandling af en genetisk tilstand
DK3875104T3 (da) Sammensætninger til behandling af ineffektiv erytropoiese
DK2773635T3 (da) Forbindelser og sammensætninger til modulering af EGFR-aktivitet
DK3363901T3 (da) Sammensætninger og fremgangsmåder til præcis identificering af mutationer
DK2812452T3 (da) Fremgangsmåder og sammensætninger til screening og behandling af udviklingsforstyrrelser
DK2914741T3 (da) Hidtil ukendte sammensætninger og fremgangsmåder til forbedring af PCR-specificitet
DK2906696T3 (da) Fremgangsmåder til modulering af c9orf72-ekspression
DK2838917T3 (da) Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler
DK2911506T3 (da) Driftreducerende sammensætninger
DK2665486T3 (da) Sammensætninger til modulering af gamma-c-cytokin-aktivitet
DK3241547T3 (da) Lyofiliseret præparat af botulinumtoksin
LT2742151T (lt) Polimerazės kompozicija
DK2855500T3 (da) Fremgangsmåder og sammensætninger til modulering af apolipoprotein (A)-ekspression
BR112013022112A2 (pt) composição
DK2766483T3 (da) Fremgangsmåder og sammensætninger til screening for og behandling af udviklingsforstyrrelser
DK2686017T3 (da) Oftalmisk sammensætning
BR112014004395A2 (pt) composição
BR112014032798A2 (pt) composição
DK2830654T3 (da) Metoder og sammensætninger til behandling af inflammation
DK2922955T3 (da) Sammensætninger og fremgangsmåder til modulering af FGFR3-ekspression
EP2842163A4 (en) NONLINEAR MEMRISTORS
BR112013033808A2 (pt) composição
EP2730619A4 (en) COMPOSITION
EP2529947A4 (en) BINDER
EP2701889A4 (en) Bonding process